Logo Image
|Articles|June 9, 2008

Give Your Input on Impact of EU Clinical Trials Directive

ICREL allows you the opportunity to give your input through a survey about the EU Clinical Trials Directive.

Brussels, Belgium-June 9, 2008-ICREL is a one-year EU FP7 project, coordinated by EFGCP with further consortium members being EORTC under leadership of Denis Lacombe, ECRIN under leadership of Jacques Demotes, The Ethics Committee of the University of Vienna under leadership of Christiane Druml, and Hospital Clinic I de Barcelona under leadership of Xavier Carné. The project aims at analyzing the impact of the Clinical Trials Directive 2001/20/EC on clinical research in Europe.

ICREL has just launched a survey, giving sampled-out stakeholders (commercial and non-commercial sponsors, ethics committees, and competent authorities) the opportunity to have their experiences taken into account. As the results of this survey will form the basis for the European Commission Directorate Entreprise for their decisions on areas to be changed in the new clinical trials legislation it is very important that we collect as much information as possible. WE NEED YOUR SUPPORT!!!!

Please go to www.eortc.be/icrel and complete the questionnaire suitable for your type of organization.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more